Abstract
BackgroundMethotrexate (MTX) is the DMARD of choice in the treatment of rheumatoid arthritis (RA). There is important variability in its therapeutic response. The identification of genetic factors related to the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
